125 related articles for article (PubMed ID: 29306501)
1. State-of-the-art technologies: In vitro and in vivo models mimicking the human drug metabolism and pharmacokinetics.
Tabata K; Hirabayashi H
Drug Metab Pharmacokinet; 2018 Feb; 33(1):1. PubMed ID: 29306501
[No Abstract] [Full Text] [Related]
2. Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control.
Hariparsad N; Ramsden D; Palamanda J; Dekeyser JG; Fahmi OA; Kenny JR; Einolf H; Mohutsky M; Pardon M; Siu YA; Chen L; Sinz M; Jones B; Walsky R; Dallas S; Balani SK; Zhang G; Buckley D; Tweedie D
Drug Metab Dispos; 2017 Oct; 45(10):1049-1059. PubMed ID: 28646080
[TBL] [Abstract][Full Text] [Related]
3. Biofabrication of a three-dimensional liver micro-organ as an in vitro drug metabolism model.
Chang R; Emami K; Wu H; Sun W
Biofabrication; 2010 Dec; 2(4):045004. PubMed ID: 21079286
[TBL] [Abstract][Full Text] [Related]
4. Prediction of hepatic and intestinal glucuronidation using in vitro-in vivo extrapolation.
Naritomi Y; Nakamori F; Furukawa T; Tabata K
Drug Metab Pharmacokinet; 2015 Feb; 30(1):21-9. PubMed ID: 25760528
[TBL] [Abstract][Full Text] [Related]
5. Workshop meeting report Organs-on-Chips: human disease models.
van de Stolpe A; den Toonder J
Lab Chip; 2013 Sep; 13(18):3449-70. PubMed ID: 23645172
[TBL] [Abstract][Full Text] [Related]
6. Imitation of drug metabolism in human liver and cytotoxicity assay using a microfluidic device coupled to mass spectrometric detection.
Mao S; Gao D; Liu W; Wei H; Lin JM
Lab Chip; 2012 Jan; 12(1):219-26. PubMed ID: 22094544
[TBL] [Abstract][Full Text] [Related]
7. A pharmaceutical industry perspective on microphysiological kidney systems for evaluation of safety for new therapies.
Phillips JA; Grandhi TSP; Davis M; Gautier JC; Hariparsad N; Keller D; Sura R; Van Vleet TR
Lab Chip; 2020 Feb; 20(3):468-476. PubMed ID: 31989145
[TBL] [Abstract][Full Text] [Related]
8. Electrochemically driven drug metabolism via a CYP1A2-UGT1A10 bienzyme confined in a graphene nano-cage.
Lu J; Zhang Y; Li H; Yu J; Liu S
Chem Commun (Camb); 2014 Nov; 50(90):13896-9. PubMed ID: 25264962
[TBL] [Abstract][Full Text] [Related]
9. The role of body-on-a-chip devices in drug and toxicity studies.
Esch MB; King TL; Shuler ML
Annu Rev Biomed Eng; 2011 Aug; 13():55-72. PubMed ID: 21513459
[TBL] [Abstract][Full Text] [Related]
10. Metabolic characterization of primary rat hepatocytes cultivated in parallel microfluidic biochips.
Legendre A; Baudoin R; Alberto G; Paullier P; Naudot M; Bricks T; Brocheton J; Jacques S; Cotton J; Leclerc E
J Pharm Sci; 2013 Sep; 102(9):3264-76. PubMed ID: 23423727
[TBL] [Abstract][Full Text] [Related]
11. A cocktail of metabolic probes demonstrates the relevance of primary human hepatocyte cultures in a microfluidic biochip for pharmaceutical drug screening.
Prot JM; Videau O; Brochot C; Legallais C; Bénech H; Leclerc E
Int J Pharm; 2011 Apr; 408(1-2):67-75. PubMed ID: 21295126
[TBL] [Abstract][Full Text] [Related]
12. Integration of microfluidic LC with HRMS for the analysis of analytes in biofluids: past, present and future.
Rainville PD; Langridge JI; Wrona MD; Wilson ID; Plumb RS
Bioanalysis; 2015; 7(11):1397-411. PubMed ID: 26110713
[TBL] [Abstract][Full Text] [Related]
13. Human and mouse artificial chromosome technologies for studies of pharmacokinetics and toxicokinetics.
Satoh D; Abe S; Kobayashi K; Nakajima Y; Oshimura M; Kazuki Y
Drug Metab Pharmacokinet; 2018 Feb; 33(1):17-30. PubMed ID: 29398301
[TBL] [Abstract][Full Text] [Related]
14. Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.
De Buck SS; Mackie CE
Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):865-78. PubMed ID: 18028030
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a liver microfluidic biochip to predict in vivo clearances of seven drugs in rats.
Baudoin R; Legendre A; Jacques S; Cotton J; Bois F; Leclerc E
J Pharm Sci; 2014 Feb; 103(2):706-18. PubMed ID: 24338834
[TBL] [Abstract][Full Text] [Related]
16. Integration of in silico and in vitro platforms for pharmacokinetic-pharmacodynamic modeling.
Sung JH; Esch MB; Shuler ML
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1063-81. PubMed ID: 20540627
[TBL] [Abstract][Full Text] [Related]
17. CYP 2C19 and UDP-glucuronosyltransferases not only for drugs but also for endobiotics.
Siest G; Fournel-Gigleux S; Magdalou J
Drug Metabol Drug Interact; 2014; 29(4):207-9. PubMed ID: 25367614
[No Abstract] [Full Text] [Related]
18. Microprinting of liver micro-organ for drug metabolism study.
Chang RC; Emami K; Jeevarajan A; Wu H; Sun W
Methods Mol Biol; 2011; 671():219-38. PubMed ID: 20967633
[TBL] [Abstract][Full Text] [Related]
19. Effect of synergists on drug metabolism.
Hodgson E; Philpot RM; Baker RC; Mailman RB
Drug Metab Dispos; 1973; 1(1):391-401. PubMed ID: 4149410
[No Abstract] [Full Text] [Related]
20. Chimeric mice with humanized liver: Application in drug metabolism and pharmacokinetics studies for drug discovery.
Naritomi Y; Sanoh S; Ohta S
Drug Metab Pharmacokinet; 2018 Feb; 33(1):31-39. PubMed ID: 29183653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
